BACKGROUND: Studies of interferon-based therapies for hepatitis C virus (HCV)-infected patients have documented variable response rates according to ethnicity. However, these studies enrolled low numbers of ethnic minorities. METHODS: Data from two multicenter trials of combination therapy for hepatitis C were analyzed to determine predictors of treatment success. The first trial was a randomized study comparing interferon administered three times weekly with daily administration. Patients in both interferon groups received weight-based ribavirin. The second trial was an observational study of daily interferon and ribavirin. Only treatment-naïve patients were included in the analysis. Ethnicity (used as a nonspecific term to include race) was determined by patient self-report. Sustained virologic response was defined as negative HCV RNA by polymerase chain reaction at 24 weeks after completion of therapy. RESULTS: A total of 661 patients (390 from the randomized trial and 271 from the observational trial) were available for analysis. Sustained virologic response was highest among Asians (61% [22/36]), followed by whites (39% [193/496]), Hispanics (23% [18/79]), and African Americans (14% [7/50]). In a multiple logistic regression model that adjusted for other factors known to affect treatment outcome, including hepatitis C genotype, Asians continued to be more likely to respond to treatment, whereas Hispanics and African Americans were less likely, as compared with whites. CONCLUSION: Sustained response rates to interferon and ribavirin therapy differ among ethnic groups. Ethnicity appears to be associated with treatment outcomes, even in a model that adjusts for other factors that influence response to therapy.
RCT Entities:
BACKGROUND: Studies of interferon-based therapies for hepatitis C virus (HCV)-infectedpatients have documented variable response rates according to ethnicity. However, these studies enrolled low numbers of ethnic minorities. METHODS: Data from two multicenter trials of combination therapy for hepatitis C were analyzed to determine predictors of treatment success. The first trial was a randomized study comparing interferon administered three times weekly with daily administration. Patients in both interferon groups received weight-based ribavirin. The second trial was an observational study of daily interferon and ribavirin. Only treatment-naïve patients were included in the analysis. Ethnicity (used as a nonspecific term to include race) was determined by patient self-report. Sustained virologic response was defined as negative HCV RNA by polymerase chain reaction at 24 weeks after completion of therapy. RESULTS: A total of 661 patients (390 from the randomized trial and 271 from the observational trial) were available for analysis. Sustained virologic response was highest among Asians (61% [22/36]), followed by whites (39% [193/496]), Hispanics (23% [18/79]), and African Americans (14% [7/50]). In a multiple logistic regression model that adjusted for other factors known to affect treatment outcome, including hepatitis C genotype, Asians continued to be more likely to respond to treatment, whereas Hispanics and African Americans were less likely, as compared with whites. CONCLUSION: Sustained response rates to interferon and ribavirin therapy differ among ethnic groups. Ethnicity appears to be associated with treatment outcomes, even in a model that adjusts for other factors that influence response to therapy.
Authors: Zoltan Pos; Silvia Selleri; Tara L Spivey; Jeanne K Wang; Hui Liu; Andrea Worschech; Marianna Sabatino; Alessandro Monaco; Susan F Leitman; Andras Falus; Ena Wang; Harvey J Alter; Francesco M Marincola Journal: Proc Natl Acad Sci U S A Date: 2009-12-22 Impact factor: 11.205
Authors: Jorge Méndez-Navarro; Ruby A Chirino; Kathleen E Corey; Emmanuel C Gorospe; Hui Zheng; Segundo Morán; Jesus A Juarez; Raymond T Chung; Margarita Dehesa-Violante Journal: Dig Dis Sci Date: 2009-12-04 Impact factor: 3.199
Authors: Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742
Authors: Firdous A Siddiqui; Murray N Ehrinpreis; James Janisse; Ravi Dhar; Elizabeth May; Milton G Mutchnick Journal: Hepatol Int Date: 2008-07-25 Impact factor: 6.047